Literature DB >> 8238012

Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia.

A Benigni1, P Boccardo, M Galbusera, J Monteagudo, L De Marco, G Remuzzi, Z M Ruggeri.   

Abstract

Patients with chronic renal failure may experience a bleeding tendency and blood loss after surgical procedures or trauma. Altered platelet function has been indicated as the major cause of uremic bleeding, but its pathogenesis remains to be clarified. In two groups of patients with chronic renal disease of various etiology, the receptor function of glycoprotein (GP) Ib and GP IIb-IIIa complex was studied. Glycoprotein Ib was assessed with both 125I-von Willebrand factor (vWF) and 125I-asialo-vWF binding to platelets. Activation-dependent receptor function of the GP IIb-IIIa complex was studied with 125I-fibrinogen and 125I-vWF binding to washed platelets stimulated with adenosine diphosphate plus epinephrine (10 mumol/L each). Flow cytometric analyses on resting and stimulated platelets were performed using an activation-dependent, anti-GP IIb-IIIa monoclonal antibody (PAC1) as well as an activation-independent antibody (LJ-P1). Binding of PAC1 also was assessed in washed and stimulated platelets and in platelet-rich plasma before and after dialysis. We found that the activation-dependent receptor function of the GP IIb-IIIa complex is defective in uremia, as shown by decreased binding of both vWF and fibrinogen to stimulated platelets. Moreover, binding of the activation-dependent anti-GP IIb-IIIa monoclonal antibody, PAC1, was significantly decreased in uremia compared with that of the activation-independent antibody, LJ-P1. Thus, the number of GP IIb-IIIa receptors expressed on the platelet membrane is normal, but their activation is impaired. In contrast to the functional abnormality of GP IIb-IIIa, the vWF-binding activity of GP Ib was normal.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238012     DOI: 10.1016/s0272-6386(12)80429-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

Review 1.  Antiplatelet agents in hemodialysis.

Authors:  Massimiliano Migliori; Vincenzo Cantaluppi; Alessia Scatena; Vincenzo Panichi
Journal:  J Nephrol       Date:  2016-12-08       Impact factor: 3.902

Review 2.  Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.

Authors:  B S Smith; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 3.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 4.  Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease.

Authors:  Alessandro Caracciolo; Renato Francesco Maria Scalise; Fabrizio Ceresa; Gianluca Bagnato; Antonio Giovanni Versace; Roberto Licordari; Silvia Perfetti; Francesca Lofrumento; Natasha Irrera; Domenico Santoro; Francesco Patanè; Gianluca Di Bella; Francesco Costa; Antonio Micari
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

5.  Effect of Xiaoyu Zhixue Tablet on the expression of platelet membrane glycoprotein I b/IX/V complex in patients with chronic renal failure.

Authors:  You Qin; Lin Shen; Fu-rong Lu; Wei Shi; Jian-guo Liu
Journal:  Chin J Integr Med       Date:  2008-08-06       Impact factor: 1.978

6.  Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.

Authors:  Menaka Pai; Neill K J Adhikari; Marlies Ostermann; Diane Heels-Ansdell; James D Douketis; Yoanna Skrobik; Ismael Qushmaq; Maureen Meade; Gordon Guyatt; William Geerts; Michael W Walsh; Mark A Crowther; Jan O Friedrich; Lisa Burry; Rinaldo Bellomo; Nilton Brandão da Silva; Rubens Costa Filho; Michael J Cox; Suzana Alves Silva; Deborah J Cook
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

Review 7.  Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges.

Authors:  Avi Sabbag; Xiaoxi Yao; Konstantinos C Siontis; Peter A Noseworthy
Journal:  Korean Circ J       Date:  2018-10       Impact factor: 3.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.